These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12867063)

  • 1. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
    Adjei AA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of farnesyltransferase inhibitors in lung cancer therapy.
    Dy GK; Adjei AA
    Clin Lung Cancer; 2002 Jul; 4(1):57-62. PubMed ID: 14653878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors in breast cancer therapy.
    Dy GK; Adjei AA
    Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitors.
    Sebti SM; Adjei AA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting Ras signaling in the therapy of breast cancer.
    Li T; Sparano JA
    Clin Breast Cancer; 2003 Feb; 3(6):405-16; discussion 417-20. PubMed ID: 12636885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
    Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
    Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD
    Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors: mechanism and applications.
    Prendergast GC; Rane N
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.